NCT02194400View on ClinicalTrials.gov

Dose Escalation Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Systemic Lupus Erythematosus
Interventions
BIOLOGICAL

RSLV-132

0.3 - 10.0 mg/kg RSLV-132 weekly for 4 weeks

Trial Locations (4)

16635

Altoona Center for Clinical Research, Duncansville

33765

Clinical Research of West Florida, Clearwater

49546

West Michigan Rheumatology, Grand Rapids

75231

Metroplex Clinical Research, Dallas

Sponsors
All Listed Sponsors
lead

Resolve Therapeutics

INDUSTRY

NCT02194400 - Dose Escalation Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus | Biotech Hunter | Biotech Hunter